Randomized, placebo-controlled trial of dalteparin for the prevention of venous
thromboembolism in acutely III medical patients × Close The Infona portal uses cookies, ie …

Background—Considerable variability exists in the use of pharmacological
thromboprophylaxis among acutely ill medical patients, partly because clinically relevant …

Background: Dalteparin and enoxaparin are recommended as thromboprophylaxis for at
least 10 days in patients undergoing abdominal surgery (AS) or hospitalized patients with …

A 15-month prospective cohort study of emergency department (ED) patients with suspected
venous thromboembolism was conducted to assess the role of low molecular weight heparin …

The utility of low-molecular-weight heparin (LMWH) in the prophylaxis of venous
thromboembolic disease has been examined using the surrogate endpoint of …

The risk of venous thromboembolism (VTE) in medical patients is generally underestimated.
However, recent studies including two large double‐blind placebo‐controlled trials, the …

PURPOSE: Venous thromboembolism (VTE) is a major cause of morbidity and mortality in
hospitalized patients. A large international study in acutely ill medical patients assessed the …

Background The use of low-molecular-weight heparin (LMWH) for the chemoprophylaxis of
venous thromboembolism (VTE) in trauma patients is supported by Level-1 evidence …

It is unclear whether thromboprophylaxis produces a consistent risk reduction in different
subgroups of medical patients at risk from venous thromboembolism. We performed a …

Dalteparin is a low molecular weight heparin (LMWH) with a mean molecular weight of
5000. Compared with unfractionated heparin (UFH), the drug has markedly improved …